Researchers at the National Eye Institute (NEI), have developed a cryopreservation and cell recovery system designed specifically for the efficient cryopreservation, transportation and subsequent thawing of monolayers and tissues on a substrate. This closed cryopreservation/defrost system allows for sterility in addition to increased viability, recovery and safety of tissues that can be used for in vitro culture or surgical transplantation.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for gene therapy for CRX retinopathies such as Leber congenital amaurosis, retinitis pigmentosa, and cone-rod dystrophy.
The National Eye Institute’s Ophthalmic Genetics and Visual Function Branch seeks partners to co-develop the protocol for iPSC to RPE differentiation and its use in clinical, screening and translational settings.
Researchers at the National Eye Institute (NEI) have generated Induced Pluripotent Stem Cells (iPS) from two Late-Onset Reginal (L-ORD) patients with a dominant mutation in CTRP5 protein and two of their unaffected siblings. All iPS cells were differentiated into authenticated Retinal Pigment Epithelium (RPE) cells. The NEI seeks licensing and/or co-development research collaborations for Metformin as an FDA-approved drug to treat Age-related Retinal Degeneration.